Logo

Genteon, USC to Study Gene Expression, Mutation in Prostate Cancer

Jul 18, 2002

NEW YORK, July 18 - Privately held genomic-tool company Genteon and the Institute for Genetic Medicine at the University of Southern California today said they will partner to study prostate cancer.

 

The USC team, led by Juergen Reichardt of the Keck School of Medicine, will get access to Genteon's Capella 400 genetic-analysis system in order to study genomic mutations and gene expression in tumor samples.

 

The Capella system, which made its debut in October 2001, is Genteon's first I-tool. It is an automated 384-capillary electrophoresis system equipped with dynamic fluorescent detection.

 

Click here for more information.

Breaking News
The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.